109 related articles for article (PubMed ID: 11041122)
1. Are the WOSCOPS clinical and economic findings generalizable to other populations? A case study for Belgium. The WOSCOPS Economic Analysis Group. West of Scotland Coronary Prevention Study.
Caro JJ; Huybrechts KF; De Backer G; De Bacquer D; Closon MC
Acta Cardiol; 2000 Aug; 55(4):239-46. PubMed ID: 11041122
[TBL] [Abstract][Full Text] [Related]
2. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study.
Caro J; Klittich W; McGuire A; Ford I; Pettitt D; Norrie J; Shepherd J
Eur Heart J; 1999 Feb; 20(4):263-8. PubMed ID: 10099920
[TBL] [Abstract][Full Text] [Related]
3. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.
Lancet; 1996 Nov; 348(9038):1339-42. PubMed ID: 8918276
[TBL] [Abstract][Full Text] [Related]
4. A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy.
Morris S
Health Econ; 1997; 6(6):589-601. PubMed ID: 9466141
[TBL] [Abstract][Full Text] [Related]
5. Preventing coronary artery disease in the West of Scotland: implications for primary prevention.
Shepherd J
Am J Cardiol; 1998 Nov; 82(10B):57T-59T. PubMed ID: 9860377
[TBL] [Abstract][Full Text] [Related]
6. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin.
Caro J; Klittich W; McGuire A; Ford I; Norrie J; Pettitt D; McMurray J; Shepherd J
BMJ; 1997 Dec; 315(7122):1577-82. PubMed ID: 9437275
[TBL] [Abstract][Full Text] [Related]
7. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
Coukell AJ; Wilde MI
Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model.
Muls E; Van Ganse E; Closon MC
Atherosclerosis; 1998 Apr; 137 Suppl():S111-6. PubMed ID: 9694550
[TBL] [Abstract][Full Text] [Related]
9. The cardiovascular event reduction tool (CERT)--a simplified cardiac risk prediction model developed from the West of Scotland Coronary Prevention Study (WOSCOPS).
L'Italien G; Ford I; Norrie J; LaPuerta P; Ehreth J; Jackson J; Shepherd J
Am J Cardiol; 2000 Mar; 85(6):720-4. PubMed ID: 12000046
[TBL] [Abstract][Full Text] [Related]
10. Primary prevention.
Am J Manag Care; 1998 Apr; 4(4 Suppl):S185-90. PubMed ID: 10184933
[No Abstract] [Full Text] [Related]
11. [Victory in primary prevention--or? Can we afford to translate results from the West-of-Scotland Study into general practice?].
Klose G
Fortschr Med; 1996 Jun; 114(17):231-2. PubMed ID: 8767302
[No Abstract] [Full Text] [Related]
12. Overlap analysis of the West of Scotland coronary prevention study (WOSCOPS).
Lim PO; Yee KM
Circulation; 1999 Aug; 100(6):686. PubMed ID: 10441109
[No Abstract] [Full Text] [Related]
13. Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials.
Iakoubova OA; Tong CH; Rowland CM; Kirchgessner TG; Young BA; Arellano AR; Shiffman D; Sabatine MS; Campos H; Packard CJ; Pfeffer MA; White TJ; Braunwald E; Shepherd J; Devlin JJ; Sacks FM
J Am Coll Cardiol; 2008 Jan; 51(4):435-43. PubMed ID: 18222353
[TBL] [Abstract][Full Text] [Related]
14. [Statin therapy of individuals with high risk for coronary disease].
Holme I
Tidsskr Nor Laegeforen; 1996 May; 116(12):1479-81. PubMed ID: 8650638
[TBL] [Abstract][Full Text] [Related]
15. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. The WOSCOPS Study Group. West of Scotland Coronary Prevention Study.
Am J Cardiol; 1995 Sep; 76(7):485-91. PubMed ID: 7653449
[TBL] [Abstract][Full Text] [Related]
16. Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS.
Iakoubova OA; Tong CH; Chokkalingam AP; Rowland CM; Kirchgessner TG; Louie JZ; Ploughman LM; Sabatine MS; Campos H; Catanese JJ; Leong DU; Young BA; Lew D; Tsuchihashi Z; Luke MM; Packard CJ; Zerba KE; Shaw PM; Shepherd J; Devlin JJ; Sacks FM
Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2763-8. PubMed ID: 17008591
[TBL] [Abstract][Full Text] [Related]
17. [WOSCOPS [West of Scotland Coronary Prevention Study]].
Furutani N; Tada N
Nihon Rinsho; 2001 Mar; 59 Suppl 3():387-92. PubMed ID: 11347100
[No Abstract] [Full Text] [Related]
18. Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial.
Avorn J; Benner J; Ford I; Ganz DA; Gaw A; Glynn RJ; Jackson J; Lagaay AM; Schneeweiss S; Walley T; Wang PS;
Control Clin Trials; 2002 Dec; 23(6):757-73. PubMed ID: 12505250
[TBL] [Abstract][Full Text] [Related]
19. Design, rational, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project--a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS).
Am J Cardiol; 1995 Nov; 76(12):899-905. PubMed ID: 7484829
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of coronary prevention.
Szucs TD; März W
Eur Heart J; 1999 Feb; 20(4):317-8. PubMed ID: 10099929
[No Abstract] [Full Text] [Related]
[Next] [New Search]
